To refine your search through our archives use our Advanced Search
Paul Douglas describes himself as a data-obsessed meteorologist, entrepreneur, author, a Republican, a devout Christian, and a global climate change skeptic-turned-believer. Douglas spent 11 years as a TV weatherman for NBC’s affiliate in Minneapolis, Minn. While there, he launched a company that produced software for 3D weather graphics. The technology caught the attention of Steven […]
Markets on Tuesday weren’t fazed by the the first partial government shutdown in 17 years. Open enrollment for Obamacare exchanges helped WellPoint shares.
A Fishers man died just after 4 p.m. Monday in a five-vehicle crash on northbound Interstate 69 that closed the busy highway for almost four hours. Michael Peed, 38, was stopped in traffic, waiting to exit at 116th Street, when another driver crashed into the back of his car. Peed’s vehicle was pushed into another car before he veered and was hit by a semi. Two others suffered non-life-threatening injuries. Lanes reopened just before 9 p.m.
Fire destroyed one house and damaged two others on the east side Tuesday morning. Indianapolis firefighters were called to the 100 block of North Denny Street at about 4:15. No injuries were reported. A family of four had been living in the house that was destroyed, but recently moved out. The neighboring houses suffered estimated damage of $20,000 to $30,000. A cause is under investigation.
A 19-year-old Indianapolis man was shot and killed on the east side Monday at about 11:25 p.m. Darren Kirk was pronounced dead in the 1100 block of North Tuxedo Street, which is east of Rural Street and west of Sherman Drive. Witnesses said a possible suspect left the scene on a bicycle.
Gander Mountain plans to open a store in Avon, Wal-Mart is expanding its presence in the metro area, and an Irish pub has opened downtown in space that’s had trouble keeping a longtime tenant.
The three-year deal will net the new North American Soccer League team Indy Eleven about $1 million over the term of the agreement and will offer the franchise a critical marketing partner.
Shares of the consumer review service have dropped more than 12 percent since the company announced Monday that Chief Technology Officer Manu Thapar had departed. The firm recently hired a new chief financial officer.
The holiday period is particularly important for retailers this year since spending was weak during the back-to-school shopping period, the second-busiest shopping months of the year.
Indiana-based manufacturer Calumet Pallet Co. plans to expand by spending $2.7 million to buy and equip a new facility in northern Indiana.
Indigo Partners LLC, led by veteran airline executive William Franke, has agreed to buy Frontier Airlines from Indianapolis-based Republic Airways Holdings Inc. for $36 million in cash. The total value of the transaction is $145 million including debt.
At-large City-County Council member Zach Adamson says that even if the apartments-and-grocery project gets an OK from city development officials on Wednesday, he might force an additional hearing.
The two Class A office buildings totaling 348,000 square feet are close to being sold after falling into foreclosure during the implosion of defunct local developer Premier Properties USA Inc.
Republican Gov. Mike Pence wrote a letter Monday urging members of the U.S. Senate to vote to repeal the medical device tax that is helping to finance Obamacare. But the Senate on Monday night voted not to repeal the tax, with all 54 Democrats voting to keep it.
Most Hoosiers are unlikely to feel much impact as the federal government experiences a partial shutdown – unless it lasts awhile.
The Indiana Department of Education reports it received 20,047 applications for vouchers for the 2013-14 school year.
For the first time in nearly two decades, the federal government staggered into a partial shutdown Monday at midnight after congressional Republicans demanded changes in the nation's health care law and President Barack Obama and Democrats refused.
Anthem Blue Cross and Blue Shield President Rob Hillman expects a slow start to the Obamacare exchanges, with fewer than one-third of uninsured people buying coverage there.
Derron Bishop has been named interim director of the Indiana University School of Medicine-Muncie campus and interim associate dean at IU School of Medicine. Bishop, a professor of cellular and integrative physiology at IU School of Medicine-Muncie, joined the IU faculty in 2002. Bishop holds a master’s degree in physiology from Ball State University and a doctorate in neurosciences from Washington University in St. Louis. Bishop succeeds T. Stuart Walker, who had served as associate dean and director since 2006. Walker will continue teaching at IU School of Medicine-Muncie as a professor of microbiology and immunology.
The Behavior Analysis Center for Autism promoted Stacy Apraez to director of operations, overseeing all four facilities run by the center. She was previously the clinical director at the Behavior Analysis Center for Autism’s Fishers facility. Apraez holds a bachelor’s from State University of New York at Brockport.
The federal Medicare program has decided, at least for now, not to reimburse health care providers who conduct diagnostic imaging tests using an Eli Lilly and Co. imaging agent that can help identify the presence of Alzheimer’s disease. Medicare will pay for those scans if they are part of a clinical trial of a drug and will consider paying for broader use in the future. But Indianapolis-based Lilly, as well as the Chicago-based Alzheimer’s Association, had been hoping for wider reimbursement now. The Alzheimer’s Association noted that it typically takes seven years for a procedure to move from clinical-trial-only reimbursement to broad reimbursement. The narrower use of Lilly’s agent, which is called Amyvid, is a small hit financially for Lilly. The bigger impact is that Lilly hoped wide use of Amyvid could help it and other companies bring drugs to market to treat Alzheimer’s. Since there are currently no effective treatments for the disease, any drug that did help with treatment would be an instant blockbuster. Lilly’s experimental drug solanezumab could have sales topping $4 billion annually if it proves effective in patients with mild Alzheimer’s disease. The drug failed its clinical trials last year when tested in a mix of mild and moderate Alzheimer’s patients, but it showed encouraging results in patients with only mild Alzheimer’s disease. The only way to identify such patients is by using a special kind of imaging test that will show deposits of a protein called amyloid—which is one of two telltale signs of Alzheimer’s disease. The imaging test is called PET, or positron emission tomography. Before Amyvid, however, the only way to view these plaques was during an autopsy.
Cancer drug Erbitux, which is partly owned by Indianapolis-based Eli Lilly and Co., extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin, according to clinical trial results released Saturday. According to Bloomberg News, the results were presented at a scientific conference in Europe by Germany-based Merck KGaA, which sells the medicine outside North America. Lilly and New York-based Bristol-Myers Squibb Co. market the drug in the United States. Erbitux generated sales for Merck of $1.2 billion last year, while Lilly realized $400 million in revenue from the drug in 2012. According to Bloomberg, the findings suggest that Erbitux, already approved in Europe as a treatment for patients with so-called KRAS wild-type tumors, may have a role in a subgroup of patients with so-called RAS wild-type cancer.
Purdue University chemistry professor Graham Cooks, whose research has played a role in the launch of several Indiana startups, was awarded the 2013 Dreyfus Prize in Chemical Sciences, the highest award possible for a chemist, during a ceremony last week. Cooks won the prize and its $250,000 payment for his innovations in the fields of mass spectrometry and analytical chemistry. Cooks and his team have fine-tuned the tools for molecular imaging for cancer diagnostics and surgery; therapeutic drug monitoring; testing for biomarkers in urine; and the identification of food-borne pathogens, bacteria, pesticides and explosives residues. His research has contributed to the technology developed by Griffin Analytical Technologies Inc., Prosolia, Inc. and InProteo LLC.
In a big disappointment, Indianapolis-based Eli Lilly and Co. reported that its experimental cancer drug ramucirumab proved no better than a placebo as a treatment for breast cancer. According to the Associated Press, the Indianapolis-based firm no longer plans to seek regulatory approval for the drug as a treatment for patients with a form of breast cancer that has spread. However, Lilly will seek approval to use ramucirumab in combination with chemotherapy in stomach cancer patients after ramucirumab performed better in a separate study on those patients. Ramucirumab extended both overall and progression-free survival times for patients with advanced gastric cancer. Lilly will seek approval from regulators for that use. It also is studying ramucirumab in colorectal and lung cancers and expects more late-stage research results next year. Ramucirumab is one of Lilly’s best hopes to produce new revenue to offset the loss of sales it has been suffering since the 2011 patent expirations on its then-best-seller, Zyprexa, and the patent expiration coming at year’s end on its current best seller, Cymbalta.
